GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (XSWX:OBSN) » Definitions » Total Liabilities

ObsEva (XSWX:OBSN) Total Liabilities : CHF7.51 Mil (As of Dec. 2022)


View and export this data going back to 2018. Start your Free Trial

What is ObsEva Total Liabilities?

ObsEva's Total Liabilities for the quarter that ended in Dec. 2022 was CHF7.51 Mil.

ObsEva's quarterly Total Liabilities declined from Jun. 2022 (CHF54.61 Mil) to Sep. 2022 (CHF19.42 Mil) and declined from Sep. 2022 (CHF19.42 Mil) to Dec. 2022 (CHF7.51 Mil).

ObsEva's annual Total Liabilities declined from Dec. 2020 (CHF50.72 Mil) to Dec. 2021 (CHF47.55 Mil) and declined from Dec. 2021 (CHF47.55 Mil) to Dec. 2022 (CHF7.51 Mil).


ObsEva Total Liabilities Historical Data

The historical data trend for ObsEva's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Total Liabilities Chart

ObsEva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 20.36 54.03 50.72 47.55 7.51

ObsEva Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 47.55 56.86 54.61 19.42 7.51

ObsEva Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

ObsEva's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.694+(0+0.274
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.542)
=7.51

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=15.412-7.903
=7.51

ObsEva's Total Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=6.694+(0+0.274
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.542)
=7.51

Total Liabilities=Total Assets (Q: Dec. 2022 )-Total Equity (Q: Dec. 2022 )
=15.412-7.903
=7.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ObsEva Total Liabilities Related Terms

Thank you for viewing the detailed overview of ObsEva's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


ObsEva (XSWX:OBSN) Business Description

Traded in Other Exchanges
N/A
Address
Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228
ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (XSWX:OBSN) Headlines

No Headlines